News Sentiment

EIKN sentiment intelligence

Eikon Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 73 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.77 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 65

directly relevant articles

Source quality 8

high-authority source matches

Trend context Trend inactive

-7.7% over one week, +1.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Eikon Therapeutics: Behind The Rough Debut (NASDAQ:EIKN)

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -7.7% Price reacting lower
Trend fit Trend inactive 1.7% over four weeks
Fair value -13.9% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 47
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 65
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Market source 9
www.marketscreener.com 5
GlobeNewswire 5
Stock Titan 4
Seeking Alpha 3
MarketBeat 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 45
Earnings 18
Analyst action 6
Guidance 3
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 73
TradingKey Direct company coverage

Eikon Therapeutics Ord Shs (EIKN) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Eikon Therapeutics Ord Shs (EIKN), detailing analyst ratings, target prices, and EPS estimates. Six analysts currently rate EIKN as a "Buy" with a target price suggesting a significant upside. The report also includes past EPS perfor

Tone
Positive 65/100
Event
Earnings
Published
22 Jun 2026 00:10
Source
TradingKey
The Globe and Mail Direct company coverage

Eikon Therapeutics Appoints Ma. Fatima Francisco to Board

Eikon Therapeutics, Inc. has appointed Ma. Fatima D. Francisco as a Class I director to its board, effective June 15, 2026. She will serve on the Compensation Committee and receive an annual cash retainer of $50,000, along with an option to purchase 85,937 shares. This appointmen

Tone
Positive 71/100
Event
Balance sheet
Published
12 Jun 2026 03:10
Source
The Globe and Mail
Stock Titan Direct company coverage

Former P&G business leader joins drug developer Eikon’s board

Eikon Therapeutics (Nasdaq: EIKN) has appointed Ma. Fatima D. Francisco, a former CEO at Procter & Gamble, as an independent director to its Board, effective June 15, 2026. She will also join the Board’s Compensation Committee. Francisco brings over 35 years of leadership experie

Tone
Positive 67/100
Event
Market update
Published
11 Jun 2026 08:12
Source
Stock Titan
Stock Titan Direct company coverage

New director and stock option grant at Eikon Therapeutics (NASDAQ: EIKN)

Eikon Therapeutics (NASDAQ: EIKN) has appointed Ma. Fatima D. Francisco to its Board of Directors as a Class I director, effective June 15, 2026. She will serve until the company's 2027 annual stockholder meeting and will join the Board's Compensation Committee. Ms. Francisco wil

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 03:10
Source
Stock Titan